Nymox Pharm Financials

NYMXF

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2024 Currency USD FYE December

This page shows Nymox Pharm (NYMXF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NYMXF FY2024 2026-04-22

External funding is functioning as the operating engine, while a shrinking liquidity cushion leaves little room for routine obligations.

In FY2024, financing inflows of $2.6M almost exactly offset operating and free-cash burn of -$2.6M. Even after that support, cash was only $74K; burn was still substantial even after roughly halving from -$5.2M two years earlier, which suggests new capital is mainly keeping the company operating rather than restoring balance-sheet flexibility.

By year-end, short-term liquidity had become extremely tight: the current ratio was 0.09x, and cash covered only a sliver of $7.4M in current liabilities. Compared with 0.7x two years earlier, the company has moved from strained liquidity to a position where near-term obligations cannot be met from on-hand resources alone.

The asset base remained very small at $654K, while liabilities nearly doubled over the last year from $3.8M to $7.4M. That pattern matters because it shows the balance sheet is not being stressed by investment into new assets, but by obligations accumulating faster than liquidity is being rebuilt.

Financial Health Signals

Financial Profile 14/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Nymox Pharm's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Nymox Pharm carries a low D/E ratio of -1.10, meaning only $-1.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 81/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Nymox Pharm's current ratio of 0.09 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$2.6M

Nymox Pharm generated -$2.6M in free cash flow in fiscal year 2024, representing cash available after capex.

Cash & Debt

$74K

YoY+5.7%

5Y CAGR-57.3%

Nymox Pharm held $74K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

95M

YoY+1.1%

5Y CAGR+5.8%

Nymox Pharm had 95M shares outstanding in fiscal year 2024. This represents an increase of 1.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Nymox Pharm invested $0 in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

NYMXF Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$0	$0	$0-100.0%	$5K-95.7%	$116K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	N/A	N/A	-$6.6M	N/A	-$11.7M+10.8%	-$13.2M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'24	Q3'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22
Revenue	N/A	$0	N/A	$0	$0	$0	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	-$1.4M	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NYMXF Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$654K+4.3%	$627K-61.4%	$1.6M+12.6%	$1.4M-66.8%	$4.3M-20.9%	$5.5M
Current Assets	$653K+4.5%	$625K-57.1%	$1.5M+40.5%	$1.0M-73.4%	$3.9M-26.9%	$5.3M
Cash & Equivalents	$74K+5.7%	$70K-95.0%	$1.4M+69.0%	$830K-77.0%	$3.6M-31.1%	$5.2M
Inventory	N/A	N/A	$0-100.0%	$34K0.0%	$34K+47.8%	$23K
Accounts Receivable	N/A	N/A	N/A	$0	$0-100.0%	$4K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.4M+95.5%	$3.8M+80.4%	$2.1M+8.1%	$1.9M-11.3%	$2.2M+7.7%	$2.0M
Current Liabilities	$7.4M+95.5%	$3.8M+80.4%	$2.1M+18.0%	$1.8M-9.1%	$2.0M-3.6%	$2.0M
Long-Term Debt	N/A	N/A	$173K-24.1%	$228K	N/A	N/A
Total Equity	-$6.8M-113.5%	-$3.2M-558.3%	-$482K+4.7%	-$506K-123.6%	$2.1M-37.8%	$3.4M
Retained Earnings	-$212.5M-2.2%	-$208.0M-4.4%	-$199.1M-3.4%	-$192.6M-7.0%	-$180.0M-7.0%	-$168.3M

Metric	Q4'24	Q3'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22
Total Assets	$654K+4.8%	$624K-0.5%	$627K-6.3%	$669K+146.9%	$271K-52.9%	$575K-64.6%	$1.6M-48.3%	$3.1M
Current Assets	$653K+4.8%	$623K-0.3%	$625K-4.4%	$654K+205.6%	$214K-53.6%	$461K-68.4%	$1.5M-49.9%	$2.9M
Cash & Equivalents	$74K+80.5%	$41K-41.4%	$70K-7.9%	$76K-42.4%	$132K-62.4%	$351K-75.0%	$1.4M-48.1%	$2.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$34K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.4M+7.4%	$6.9M+82.1%	$3.8M+47.8%	$2.6M-18.3%	$3.1M+32.6%	$2.4M+12.7%	$2.1M-11.0%	$2.4M
Current Liabilities	$7.4M+7.4%	$6.9M+82.1%	$3.8M+47.8%	$2.6M-18.3%	$3.1M+32.6%	$2.4M+12.7%	$2.1M-10.6%	$2.4M
Long-Term Debt	N/A	N/A	N/A	$11K-80.0%	$55K-51.8%	$114K-34.1%	$173K-19.9%	$216K
Total Equity	-$6.8M-7.6%	-$6.3M-98.4%	-$3.2M-66.8%	-$1.9M+33.9%	-$2.9M-59.9%	-$1.8M-273.2%	-$482K-162.4%	$773K
Retained Earnings	-$212.5M	N/A	-$208.0M	N/A	N/A	N/A	-$199.1M	N/A

NYMXF Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$2.6M	N/A	-$5.2M	N/A	-$10.0M-35.1%	-$7.4M
Capital Expenditures	$0-100.0%	$3K	$0-100.0%	$6K-53.8%	$13K	$0
Free Cash Flow	-$2.6M	N/A	-$5.2M	N/A	-$10.1M-35.3%	-$7.4M
Investing Cash Flow	$0+100.0%	-$3K	$0+100.0%	-$6K+53.8%	-$13K	$0
Financing Cash Flow	$2.6M-4.5%	$2.7M-52.8%	$5.8M-18.0%	$7.0M-16.4%	$8.4M+78.3%	$4.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'24	Q3'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22
Operating Cash Flow	-$717K	N/A	-$897K+29.0%	-$1.3M-38.9%	-$909K+8.0%	-$988K+20.9%	-$1.2M+4.4%	-$1.3M
Capital Expenditures	$0	N/A	$0	$0	$0-100.0%	$3K	$0	$0
Free Cash Flow	-$717K	N/A	-$897K+29.0%	-$1.3M-38.9%	-$909K+8.3%	-$991K+20.7%	-$1.2M+4.4%	-$1.3M
Investing Cash Flow	$0	N/A	$0	$0	$0+100.0%	-$3K	$0	$0
Financing Cash Flow	$750K	N/A	$891K-26.2%	$1.2M+74.9%	$690K+1231.1%	-$61K-17.3%	-$52K+13.3%	-$60K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NYMXF Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	-234760.0%-223413.5pp	-11346.6%
Return on Equity	N/A	N/A	N/A	N/A	-547.2%-165.5pp	-381.7%
Return on Assets	N/A	N/A	-404.7%	N/A	-270.3%-30.5pp	-239.8%
Current Ratio	0.09-0.1	0.16-0.5	0.69+0.1	0.58-1.4	1.98-0.6	2.61
Debt-to-Equity	-1.10+0.1	-1.20-0.8	-0.36+0.1	-0.45-1.5	1.02+0.4	0.59
FCF Margin	N/A	N/A	N/A	N/A	-201000.0%-194594.8pp	-6405.2%

Metric	Q4'24	Q3'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	-241.2%	N/A	N/A
Current Ratio	0.090.0	0.09-0.1	0.16-0.1	0.25+0.2	0.07-0.1	0.19-0.5	0.69-0.5	1.24
Debt-to-Equity	-1.100.0	-1.10+0.1	-1.20-1.2	-0.01+0.0	-0.02+0.0	-0.06+0.3	-0.36-0.6	0.28
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$6.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Tron Group TGRP

$4.2M

ASEP MED HLDGS INC SEPSF

$4.3M

Biophytis Sa BPTSY

$4.9M

Orgenesis Inc ORGS

$7.9M

Kane Biotech Inc KNBIF

$4.0M

Frequently Asked Questions

What is Nymox Pharm's free cash flow?

Nymox Pharm (NYMXF) generated -$2.6M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Nymox Pharm's operating cash flow?

Nymox Pharm (NYMXF) generated -$2.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Nymox Pharm's total assets?

Nymox Pharm (NYMXF) had $654K in total assets as of fiscal year 2024, including both current and long-term assets.

What are Nymox Pharm's capital expenditures?

Nymox Pharm (NYMXF) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How many shares does Nymox Pharm have outstanding?

Nymox Pharm (NYMXF) had 95M shares outstanding as of fiscal year 2024.

What is Nymox Pharm's current ratio?

Nymox Pharm (NYMXF) had a current ratio of 0.09 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Nymox Pharm's debt-to-equity ratio?

Nymox Pharm (NYMXF) had a debt-to-equity ratio of -1.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nymox Pharm's cash runway?

Based on fiscal year 2024 data, Nymox Pharm (NYMXF) had $74K in cash against an annual operating cash burn of $2.6M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Nymox Pharm's debt-to-equity ratio negative or unusual?

Nymox Pharm (NYMXF) has negative shareholder equity of -$6.8M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Nymox Pharm?

Nymox Pharm (NYMXF) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.